Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
BMC Cancer
January 2025
Centre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.
Background: Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2, causing constitutive activation of the kinase and activation of downstream signalling.
View Article and Find Full Text PDFAlkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
Br J Cancer
January 2025
Mayo Clinic, Rochester, MN, USA.
Background: Alkaline phosphatase (ALP) declines and pain responses can occur during radium-223 (Ra) treatment, but their association with treatment outcomes is unclear.
Methods: For patients with metastatic castration-resistant prostate cancer treated with Ra in the REASSURE study, we investigated whether ALP decline (Week 12) and/or pain response (during treatment) are associated with improved overall survival (OS). The Brief Pain Inventory-Short Form (BPI-SF) was used to assess pain at baseline and pain response (in patients with baseline BPI-SF score ≥2).
Evaluation of the implementation in primary care of genetic testing for the screening of MODY2 (iMOgene): protocol for an implementation pilot study.
BMJ Open
January 2025
Research Centre of Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (CIUSSS-SLSJ), Saguenay, Quebec, Canada
Introduction: MODY2 (maturity-onset diabetes of the young type 2, MIM125851) is a monogenic diabetes with an autosomal dominant transmission caused by a variant of the gene. MODY2 is often confused with type 1 or type 2 diabetes, but despite a slightly elevated blood glucose level, it does not induce long-term vascular complications, nor does it require pharmacological treatment. Genetic testing for the diagnosis of MODY2 is currently reserved for genetic specialists and some physicians.
View Article and Find Full Text PDFPredatory journals: what can we do to protect their prey?
Lancet
January 2025
La Tunisie Médicale, Tunis, Tunisia.
ENT specialists' knowledge and their skills in detecting maxillary sinusitis of odontogenic origin, a cross-sectional study.
Am J Otolaryngol
December 2024
Pediatric Otolaryngology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Odontogenic maxillary sinusitis (OMS) is recognized in literature, but diagnosing it is challenging due to its different and overlapping clinical presentations of it. Misdiagnosis can lead to persistent symptoms and clinical burden. Interestingly, recent guidelines from the American Academy of Otolaryngology-Head and Neck Surgery lack recommendations for dental evaluation in adult sinusitis cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!